- Motley Fool•yesterday
A look through rose-colored glasses at Gilead Sciences' possible future.
- Motley Fool•3 days ago
Short-term pain with Molina Healthcare, Gilead Sciences, and Express Scripts stocks could still turn into long-term gains.
- Zacks•4 days ago
Mylan N.V. (MYL) obtained a tentative approval from the FDA under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for the New Drug Application for cocktail therapy Sustiva, lamivudine and Viread, 400 mg/300 mg/300 mg (TLE400).
GILD : Summary for Gilead Sciences, Inc. - Yahoo Finance
Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||67.35 x 100|
|Ask||67.64 x 600|
|Day's Range||67.21 - 67.87|
|52 Week Range||65.38 - 103.10|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||6.79|
|Dividend & Yield||2.08 (3.08%)|
|1y Target Est||N/A|